2019 | Peter T. Nelson, Dennis W. Dickson, John Q. Trojanowski, Clifford R. Jack Jr., Patricia A. Boyle, Konstantinos Arfanakis, Rosa Rademakers, Irina Alafuzoff, Johannes Attems, Carol Brayne, Ian T.S. Coyle-Gilchrist, Helena C. Chui, David W. Fardo, Margaret E. Flanagan, Glenda Halliday, Sivi R.K. Hokkanen, Sally Hunter, Gregory A. Jicha, Yuriko Katsumata, Claudia H. Kawas, Dirk Keene, Gabor G. Kovacs, Walter A. Kukull, Allan I. Levey, Nazanin Makkinejad, Thomas J. Montine, Shigeo Murayama, Melissa E. Murray, Sukriti Nag, Robert A. Rissman, William W. Seeley, Reisa A. Sperling, Charles L. White III, Lei Yu and Julie A. Schneider
The article reviews the recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE), which is characterized by a stereotypical TDP-43 proteinopathy in older adults, often associated with hippocampal sclerosis. LATE is distinguished from frontotemporal lobar degeneration with TDP-43 pathology by its epidemiology and neuroanatomical distribution of TDP-43 proteinopathy. Community-based autopsy studies show that approximately 25% of brains have sufficient LATE neuropathological changes (LATE-NC) to be associated with cognitive impairment. Many subjects with LATE-NC have comorbid brain pathologies, including amyloid-β plaques and tauopathy. Given the increasing prevalence of advanced age, LATE has an expanding but under-recognized impact on public health. The article proposes new terminology and diagnostic criteria for LATE, including guidelines for diagnosis and staging of LATE-NC. It also highlights the need for specific biomarkers and targeted therapies to address the growing burden of LATE.The article reviews the recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE), which is characterized by a stereotypical TDP-43 proteinopathy in older adults, often associated with hippocampal sclerosis. LATE is distinguished from frontotemporal lobar degeneration with TDP-43 pathology by its epidemiology and neuroanatomical distribution of TDP-43 proteinopathy. Community-based autopsy studies show that approximately 25% of brains have sufficient LATE neuropathological changes (LATE-NC) to be associated with cognitive impairment. Many subjects with LATE-NC have comorbid brain pathologies, including amyloid-β plaques and tauopathy. Given the increasing prevalence of advanced age, LATE has an expanding but under-recognized impact on public health. The article proposes new terminology and diagnostic criteria for LATE, including guidelines for diagnosis and staging of LATE-NC. It also highlights the need for specific biomarkers and targeted therapies to address the growing burden of LATE.